Suppr超能文献

卡托普利治疗自发性高血压大鼠预防肾硬化和心脏肥大

Prevention of nephrosclerosis and cardiac hypertrophy by captopril treatment of spontaneously hypertensive rats.

作者信息

Ohashi H, Matsunaga M, Yoshida H, Nagai H, Pak C H, Hara A, Kawai C

出版信息

Jpn Circ J. 1986 Feb;50(2):140-6. doi: 10.1253/jcj.50.140.

Abstract

The relationship between hypertension and cardiovascular damage was assessed in three groups of spontaneously hypertensive rats (SHR): 1. stroke prone SHR (SHR-SP) treated orally with an angiotensin I converting enzyme inhibitor (captopril) (100-400 mg/L in the drinking water) from 6 to 35 weeks of age, 2. SHR-SP maintained on tap water until 30 weeks of age, 3. stroke resistant SHR (SHR-SR) maintained on tap water. The controls were Wister Kyoto rats (WKY) maintained on tap water. Captopril-treated SHR-SP showed blood pressure lower than that of untreated SHR-SP, similar to SHR-SR. The ratio of heart weight to body weight was 0.55% in SHR-SP, 0.39% in captopril-treated SHR-SP, 0.46% in SHR-SR, and 0.39% in WKY. The kidneys of SHR-SP showed glomerular sclerosis, glomerular fibrosis, tubular casts, interstitial cell infiltration and vascular wall thickening or hyperplasia of the small arteries and arterioles. The severe glomerular sclerosis was mostly distributed in the inner and middle portions of cortex. Immunohistological study showed IgG, C3 and fibrinogen in the glomeruli and arterioles in SHR-SP. In captopril-treated SHR-SP, similar to SHR-SR, only minor histological changes were seen and there was no deposition of IgG, C3 or fibrinogen. No changes were seen in WKY. Thus, it was concluded that nephrosclerosis and cardiac hypertrophy in SHR-SP are prevented by captopril. The role of the renin-angiotensin and kallikrein-kinin systems in organ pathogenesis in SHR-SP is discussed.

摘要

在三组自发性高血压大鼠(SHR)中评估了高血压与心血管损伤之间的关系:1. 易中风SHR(SHR-SP),从6周龄至35周龄口服血管紧张素I转换酶抑制剂(卡托普利)(饮用水中浓度为100 - 400 mg/L);2. SHR-SP饮用自来水至30周龄;3. 抗中风SHR(SHR-SR)饮用自来水。对照组为饮用自来水的Wister Kyoto大鼠(WKY)。卡托普利治疗的SHR-SP血压低于未治疗的SHR-SP,与SHR-SR相似。SHR-SP的心脏重量与体重之比为0.55%,卡托普利治疗的SHR-SP为0.39%,SHR-SR为0.46%,WKY为0.39%。SHR-SP的肾脏表现为肾小球硬化、肾小球纤维化、肾小管管型、间质细胞浸润以及小动脉和微动脉的血管壁增厚或增生。严重的肾小球硬化主要分布在皮质的内、中部分。免疫组织学研究显示SHR-SP的肾小球和小动脉中有IgG、C3和纤维蛋白原。在卡托普利治疗的SHR-SP中,与SHR-SR相似,仅见轻微的组织学变化,且无IgG、C3或纤维蛋白原沉积。WKY未见变化。因此,得出结论:卡托普利可预防SHR-SP中的肾硬化和心脏肥大。并讨论了肾素 - 血管紧张素和激肽释放酶 - 激肽系统在SHR-SP器官发病机制中的作用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验